TITLE

The four colours of biotechnology

AUTHOR(S)
Aldridge, Susan
PUB. DATE
January 2009
SOURCE
Pharmaceutical Technology Europe;Jan2009, Vol. 21 Issue 1, p12
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the different sectors of the biotechnology industry symbolized by four colors. Red is for the medical sector, white or grey for the industrial sector, green is for plant and environmental biotechnology and the last is blue for marine biotechnology. All four sectors of biotechnology contribute to the pharmaceutical industry.
ACCESSION #
37289129

 

Related Articles

  • The pharma-sea. Jones, Arthur; Isy-Schwart, Lionel // FW;11/22/94, Vol. 163 Issue 24, p24 

    Focuses on marine biotechnology in the United States. Use of marine biotechnology to research for medicines; Investments of Japanese corporations on marine biotechnology; Sample collection of marine life; Biotechnologists' comments. INSETS: Jules Verne got there first.;Billions for barnacles..

  • An Outsourcing EDGE. May, Mike // Drug Discovery & Development;Jan2007, Vol. 10 Issue 1, p24 

    The article shares insights related to outsourcing for biotechnology and pharmacy companies in the U.S. It is claimed that capital efficiency is a key driver in making outsourcing decisions since drug companies need to focus on what functions they can fund in the most cost-effective manner. The...

  • BIOTECH BUSINESS CONTINUITY AND RECOVERY STRATEGIES.  // Biotech Financial Reports;May2009, Vol. 16 Issue 5, p1 

    The article focuses on the business continuity planning (BCP). It notes that BCP is used by companies to prevent disruptions in operations especially in the area of pharmaceutical and biotech manufacturing. Furthermore, BCP can give a company a flexible and focused framework for addressing...

  • The Changing Core Laboratory. Markin, Jeff // Applied Clinical Trials;Jan2009 Supplement, p10 

    The article focuses on the impact of Metrics Champion Consortium (MCC), continuous improvement programs, on biotechnology and pharmaceutical industry and service providers, particularly imaging core laboratories. It highlights qualities of laboratories that meet the need of sponsors to...

  • Open-minded innovation: Collaborating to create the best environment for changing the practice of medicine. Xu, Stella // Australasian Biotechnology;Oct2010, Vol. 20 Issue 3, p34 

    The article emphasizes the importance of collaboration and keeping an open mind for accessing external innovation in the field of pharmaceuticals and biotechnology. Collaboration and partnerships provide results which can be considered as breakthroughs in the field of healthcare. Partnerships...

  • Quide3l gains FDA approval for rapid flu test. Webb // San Diego Business Journal;10/11/99, Vol. 20 Issue 41, p29 

    Cites developments concerning biotechnology companies in the San Diego, California area as of October 11, 1999. Includes Quidel Corp.'s receipt of government approval for the marketing of its QuickVue Influenza Test in the United States; Idec Pharmaceuticals Corp.'s testing of the Idec-114 drug...

  • Employment and management trends in the biotechnolgy industry. Larbey, Cynthia // Journal of Commercial Biotechnology;Spring2002, Vol. 8 Issue 4, p298 

    This paper takes a look at the major influences on the biotechnology industry and how they are currently affecting employment and management trends. It takes a brief look at the impact of the economic environment, the pharmaceutical industry, the role of geography, the employment stages faced by...

  • Writing a Prescription For Robust Health. Goldblatt, Dan // Business News New Jersey;01/02/2001, Vol. 14 Issue 1, p30 

    Discusses the positive outlook for the New Jersey's pharmaceutical and biotechnology industries in 2001. Increase in research and development spending; Product approvals received by drug companies in 2000; Decline in revenues from drugs that will lose patent protection by 2002; Consolidation...

  • Financing Picks Up. Burrill, G. Steven // BioPharm International;Sep2001, Vol. 14 Issue 9, p48 

    Discusses the financial recovery of biotechnology companies in the United States and Europe. Predictions regarding increased merger and acquisition activity within the industry; Market value of the U.S. biotechnology market; Prediction that investments in the industry is likely to improve in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics